Ethical Pharmaceuticals Market By Drug Class 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Ethical Pharmaceuticals Market
Ethical Pharmaceuticals Market: By Drug Class (Lipid regulators, Narcotic analgesics, ACE inhibitors, Respiratory agents, Diuretics, Calcium antagonists, Hormonal contraceptives, Others) & By Geography (Europe, North America, Others) -Forecast (2016-2021)
Report Code : HCR 0206
Updated Date: 07 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Ethical pharmaceuticals also known as prescription drugs are the classes of drugs which can only be sold by a pharmacist when authorised by a written prescription from a medical practitioner. These are the classes of licensed drugs which are regulated by various legislations in order to avoid any misuse of the drugs or to avoid any unwanted consequences of consumption of these drugs. Global market for ethical pharmaceuticals is expected to be driven by increasing geriatric population and people with chronic lifestyle diseases.

This report identifies the ethical pharmaceuticals market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to ethical pharmaceuticals market.
 
Ethical Pharmaceuticals Market

Globally, North America dominated the market for ethical pharmaceuticals in 2015 due to a large population base suffering from life style related health issues, developed medical infrastructure, high health issue awareness and easy access of practitioners. North America is expected to continue its domination during the period of study and was followed by Europe and Asia-Pacific as the second and third largest markets respectively in 2015. Growing population with life style related chronic health issues and rapidly developing medical infrastructure makes Asia-Pacific, the fastest growing regional market during the period of study.

This report on ethical pharmaceuticals also covers different drug classes of ethical pharmaceuticals, and market size in various geographical regions.
  • The report covers major drug classes of ethical pharmaceuticals, some of the major drug classes covered here are as follows: Lipid regulators, Narcotic analgesics, ACE inhibitors, Respiratory agents, Diuretics, Calcium antagonists, Hormonal contraceptives, Penicillin, Vitamin and minerals
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for ethical pharmaceuticals in each of the region.

Sample Companies Profiled in this Report are:

  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson     
  • Eli Lilly and Company      
  • Merck & Co., Inc.
  • 10+
1. Ethical Pharmaceuticals – Market Overview
2. Executive Summary
3. 
Ethical Pharmaceuticals Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Ethical Pharmaceuticals – Market Forces
   4.1. Drivers
      4.1.1. Growing number of geriatric population and people with chronic lifestyle diseases
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Ethical Pharmaceuticals Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Ethical Pharmaceuticals Market, By Drug Class
   6.1. Lipid regulators
   6.2. Narcotic analgesics
   6.3. ACE inhibitors
   6.4. Respiratory agents
   6.5. Diuretics
   6.6. Calcium antagonists
   6.7. Hormonal contraceptives
   6.8. Penicillin
   6.9. Vitamin and minerals
7. Ethical Pharmaceuticals Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Ethical Pharmaceuticals – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. Teva Pharmaceutical Industries Ltd.
      9.1.1. Introduction
      9.1.2. Financials
      9.1.3. Key Insights
      9.1.4. Key Strategy
      9.1.5. Product Portfolio
      9.1.6. SWOT Analysis
   9.2. GlaxoSmithKline plc
      9.2.1. Introduction
      9.2.2. Financials
      9.2.3. Key Insights
      9.2.4. Key Strategy
      9.2.5. Product Portfolio
      9.2.6. SWOT Analysis
   9.3. Johnson & Johnson     
      9.3.1. Introduction
      9.3.2. Financials
      9.3.3. Key Insights
      9.3.4. Key Strategy
      9.3.5. Product Portfolio
      9.3.6. SWOT Analysis
   9.4. Novartis AG    
      9.4.1. Introduction
      9.4.2. Financials
      9.4.3. Key Insights
      9.4.4. Key Strategy
      9.4.5. Product Portfolio
      9.4.6. SWOT Analysis
   9.5. Pfizer, Inc.  
      9.5.1. Introduction
      9.5.2. Financials
      9.5.3. Key Insights
      9.5.4. Key Strategy
      9.5.5. Product Portfolio
      9.5.6. SWOT Analysis
   9.6. Sanofi S.A.   
      9.6.1. Introduction
      9.6.2. Financials
      9.6.3. Key Insights
      9.6.4. Key Strategy
      9.6.5. Product Portfolio
      9.6.6. SWOT Analysis
   9.7. Merck & Co., Inc.  
      9.7.1. Introduction
      9.7.2. Financials
      9.7.3. Key Insights
      9.7.4. Key Strategy
      9.7.5. Product Portfolio
      9.7.6. SWOT Analysis
   9.8. AstraZeneca plc      
      9.8.1. Introduction
      9.8.2. Financials
      9.8.3. Key Insights
      9.8.4. Key Strategy
      9.8.5. Product Portfolio
      9.8.6. SWOT Analysis
   9.9. Bristol-Myers Squibb
      9.9.1. Introduction
      9.9.2. Financials
      9.9.3. Key Insights
      9.9.4. Key Strategy
      9.9.5. Product Portfolio
      9.9.6. SWOT Analysis
   9.10. Eli Lilly and Company      
      9.10.1. Introduction
      9.10.2. Financials
      9.10.3. Key Insights
      9.10.4. Key Strategy
      9.10.5. Product Portfolio
      9.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll